Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (281-290 of 303) with videos related to

Pageof 31
Sort By:
The Journal of Rheumatology|October 16, 2020
Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus ErythematosusDaniela Dominguez, Sylvia Kamphuis, Joseph Beyene, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Transplantation and Cellular Therapy|February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for MyelofibrosisTania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Acute myeloid leukemia, version 2.2013Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Blood Cancer Journal|October 31, 2021
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemiaJoshua F Zeidner, Tara L Lin, Carlos E Vigil, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 11, 2012
NCCN Clinical Practice Guidelines Acute myeloid leukemiaMargaret R O'Donnell, Camille N Abboud, Jessica Altman, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.
Pageof 31

Showing results (281-290 of 303) with videos related to

Sort By:
Pageof 31
The Journal of Rheumatology|October 16, 2020
Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus ErythematosusDaniela Dominguez, Sylvia Kamphuis, Joseph Beyene, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Transplantation and Cellular Therapy|February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for MyelofibrosisTania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Acute myeloid leukemia, version 2.2013Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Blood Cancer Journal|October 31, 2021
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemiaJoshua F Zeidner, Tara L Lin, Carlos E Vigil, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 11, 2012
NCCN Clinical Practice Guidelines Acute myeloid leukemiaMargaret R O'Donnell, Camille N Abboud, Jessica Altman, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.
Pageof 31